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otal knee arthroplasty is a common surgical procedure.
Long-term observational studies have indicated that
more than 90% of modern primary total knee replace-
ments survive for at least fifteen years1. However, a substantial
proportion of patients have a poor functional result and per-
sistent knee pain2. Many of these poor results are attributed to
problems arising from the patellofemoral joint, and there is
considerable debate regarding whether the patella should be
resurfaced at the time of the primary total knee arthroplasty.
Previous nonrandomized cohort studies, small randomized trials,
and systematic reviews have not resolved the uncertainty re-
garding the benefits of patellar resurfacing3-18, as many of the
previous randomized controlled trials have not been ade-
quately powered.
The Knee Arthroplasty Trial (KAT) was initiated in 1999
to assess the merits of four knee replacement options: patellar
resurfacing, a metal-backed tibia, mobile bearing surfaces, and
unicompartmental replacement. The study was a partial facto-
rial, pragmatic, multicenter, randomized controlled trial designed
to assess clinical outcomes, complications, and cost-effectiveness.
The aim of a pragmatic trial is to estimate effectiveness rather
than efficacy within routine clinical practice19. Full details of the
KAT study and the two-year outcomes have been published
previously20. The purpose of the present report is to present the
five-year clinical outcomes, complications, and health care costs
in the portion of the study that addressed whether or not the
patella should be resurfaced during the primary arthroplasty
procedure. To our knowledge, it is the largest randomized trial
to address this issue to date.
Materials and Methods
The trial was approved by the relevant national and local research ethicscommittees and was registered in a public trials registry (International
Standard Randomized Trial No. ISRCTN45837371). Any orthopaedic sur-
geon in the United Kingdomwho performed knee replacements regularly was
eligible to participate in the trial. One hundred and sixteen surgeons in thirty-
four centers in the United Kingdom participated in the KATstudy, and ninety-
nine (85%) of these surgeons recruited patients to the patellar resurfacing
comparison.
All patients under the care of a participating surgeon were potentially
eligible for inclusion in the overall study if they were scheduled to undergo a
primary total knee arthroplasty. A patient was not eligible for a particular com-
parison within the study if the surgeon considered only one of the two surgical
procedures in that comparison to be indicated.
Suitable alternative prosthesis designs were available for each of the
possible randomized choices within the study. Surgeons followed their
standard practice, and the outcomes would thus not have been influenced
by a so-called learning-curve effect. We did not influence surgeons regarding
the choice between a cruciate-retaining and a cruciate-substituting implant.
All other aspects of patient care were left to the discretion of the responsible
surgeon.
The primary outcome measure was the functional status as measured
with use of the Oxford Knee Score (OKS)
21
, which was developed specifically to
measure outcomes of knee replacement and has been shown by independent
studies to perform well compared with alternative outcome instruments
22-24
. A
power calculation indicated that 1400 participants would provide 80% power to
detect a 1.5-point difference in theOKS (two-tailed p < 0.05). Secondary outcome
measures included the quality of life as measured with use of the Short Form-12
(SF-12)
25
and the EuroQoL 5D (EQ-5D)
26,27
, intraoperative and postoper-
ative complications including the need for subsequent surgery, cost, and cost-
effectiveness. In addition, question 12 of the OKS was analyzed in isolation as a
secondary outcome since it assesses the ability to walk downstairs, which is one
aspect of knee function that patellar resurfacing may influence. The five possible
responses for question 12 were ‘‘No, impossible’’ (scored as 0), ‘‘With extreme
difficulty’’ (1), ‘‘With moderate difficulty (2), ‘‘With little difficulty’’ (3), and ‘‘Yes,
easily’’ (4).
Patients were randomized to receive or not receive patellar resurfacing
with use of computer-generated random numbers obtained via an automated,
centralized telephone service. Randomization was stratified by surgeon, with
minimization according to patient age (less than 60 years, 60 to 79 years, or 80
years or older), sex, and location of disease (one knee, both knees, or general
arthritis). Patients were not blinded to treatment allocation.
Preoperative, operative, and postoperative data on the surgery, knee
components used, length of hospital stay, operative time, and complications
were collected prospectively on standard forms. This information was sup-
plemented with routinely collected information from the Hospital Episode
Statistics (HES) database in England or the Information Services Division (ISD)
in Scotland if such data were available. Data describing functional status and
quality of life were obtained directly from questionnaires completed by par-
ticipants preoperatively, at three months after the operation, at one year, and
annually thereafter. Patients who did not return the questionnaire were offered
the option of completing the questionnaire over the telephone. The ques-
tionnaire included the OKS, SF-12, and EQ-5D, as well as questions regarding
hospital admissions and ambulatory consultations with general practitioners,
physical therapists, and hospital physicians related to the involved knee. The
patient’s case notes were reviewed if the questionnaire or the HES or ISD data
indicated subsequent knee-related surgery or hospital readmissions, and such
events were classified according to severity. The severity categories were (1)
patella-related reoperation (late patellar resurfacing or surgical treatment of
a patellar fracture), (2) major reoperation (revision arthroplasty or ampu-
tation), (3) minor or intermediate reoperation (an operation with a degree of
severity between that of wound closure and that of manipulation under anes-
thesia, or an operation due to arthrofibrosis), and (4) readmission or other
subsequent intervention (any readmission or any intervention such as an
injection).
List prices for knee components were obtained from manufacturers; a
30% discount was applied to list prices to reflect the price likely to be paid by a
typical hospital, although the actual discounts would vary. Other estimated unit
costs are listed in the Appendix, along with the sources from which they were
derived. Unit costs and resource use data were combined to calculate the total
cost per patient associated with the knee arthroplasty during the first five years.
The total cost included the costs associated with the hospital stay for the pri-
mary arthroplasty and for any related readmissions, the operating room used
for the primary arthroplasty and for any subsequent related surgery, the knee
arthroplasty components, blood transfusions, computed tomography or ul-
trasonographic scans, and consultations with general practitioners, physical
therapists, and outpatient physicians related to the involved knee. Cost
analyses were conducted from the perspective of the health system and thus
excluded any costs incurred by patients or their employers. Costs incurred
after the first postoperative year were discounted at 3.5% per year
28
. Full
details of the cost analysis and the results of sensitivity analyses will be re-
ported separately.
Data were analyzed on the basis of the procedure allocation, regardless
of the method of knee replacement that was actually used (i.e., analysis was
performed on the basis of the intention-to-treat principle). Functional status
and quality-of-life outcomes were compared with use of an analysis of co-
variance that adjusted for baseline scores and the minimization factors. The
proportion of patients with readmissions and/or subsequent surgery was an-
alyzed with use of logistic regression analysis; rare events were analyzed with use
of the exact logistic regression command in Stata Version 11.0 (StataCorp,
College Station, Texas). Descriptive statistics are presented when appropriate,
and effect sizes are presented with associated 95% confidence intervals (CIs)
estimated with use of robust standard errors to account for potential surgeon
effects.
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Since 44% (732) of the 1671 patients analyzed had missing data for at
least one resource use item and some missing data (for example, length of stay
for a revision procedure) were not missing completely at random, a complete
case analysis of cost data would have been inefficient and prone to bias
29
. We
therefore used the ICE command
30
in Stata to impute missing data regarding
component prices and resources with use of multiple imputation
29,31
. Multiple
imputation predicts missing values by iteratively estimating regression models
based on observed and imputed data; this enabled missing data on specific re-
source items to be imputed on the basis of the patient’s age, sex, and treatment
allocation; the quantities of other resources that they required; and the corre-
lations observed among these variables for other patients. Imputation was
performed on the entire trial dataset (with the exception of patients excluded
after randomization). Costs are presented as the mean and standard deviation
for each group and are expressed in pounds Sterling at 2007-2008 prices (£1 =
US$2 in 2007-2008). The mean difference (and 95% CI) between groups was
calculated across the ten imputed datasets with use of the MICOMBINE com-
mand in Stata.
Source of Funding
The Knee Arthroplasty Trial was funded by the National Institute for Health
Research (NIHR) Health Technology Assessment programme (project
number 95/10/01). Additional funding for research support at the clinical
centers was provided by Stryker Orthopaedics (formerly Howmedica Os-
teonics) (Newbury, Berkshire, United Kingdom); Zimmer (Swindon, Wilt-
shire, United Kingdom); DePuy, a Johnson & Johnson company (Leeds, United
Kingdom); Corin Medical (Cirencester, Gloucestershire, United Kingdom);
Smith & Nephew Healthcare (Cambridge, United Kingdom); Biomet Merck
(Bridgend, South Wales, United Kingdom); and Wright Medical (formerly
Wright Cremascoli) (Woking, Surrey, United Kingdom). Core funding for
the Health Services Research Unit was provided by the Chief Scientist Office
of the Scottish Government Health Directorates. The Musculoskeletal Bio-
medical Research Unit in Oxford was funded by the NIHR. The Health
Economics Research Centre in Oxford received some core funding from
NIHR.
Results
From July 1999 to January 2003, 4070 potentially eligible pa-tients were identified and 2374 (58%) gave their consent and
were randomized for treatment. Of these, 1715 patients were
suitable for the comparison assessing patellar resurfacing. Forty
patients were subsequently withdrawn, two died prior to sur-
gery, and the procedure received by sixteen could not be de-
termined (Fig. 1). Of the 1715 patients formally enrolled in the
trial comparison, 1424 (83%) received the allocated proce-
dure. Ninety-five (11.1%) of the 854 patients who were al-
located to receive no resurfacing had the patella resurfaced, and
138 (16.0%) of the 861 patients who were allocated to resurfacing
did not have the patella resurfaced. Themost common reasons for
Fig. 1
CONSORT (Consolidated Standards of Reporting Trials) diagram showing the flow of patients through the trial.
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noncompliance were a clinical decision made at the time of the
operation or a logistical constraint such as unavailability of the
prostheses at the time of surgery. The two randomized groups
were well matched (see Appendix), as described previously 20.
The mean age was seventy years in both groups, and the per-
centage of male patients was 45% in the patellar resurfacing
group and 44% in the nonresurfacing group. The mean body-
mass index was 30 kg/m2 in both groups, and the percentage
of patients with knee osteoarthritis was approximately 96%
in both groups. The distribution of scores on the American
Society of Anesthesiologists (ASA) classification system and the
percentage of patients with a history of previous knee surgery
were similar in the two groups.
There was no statistically significant difference between
the groups either in the overall rate of short-term complica-
tions20 or in any of the patient-assessed outcomes at baseline or
at any subsequent time point (Fig. 2, Table I). The mean OKS
value in both groups increased from 18 points preoperatively to
35 points at five years postoperatively. The difference in the
OKS value between the groups was 0.59 point (95% CI, –0.58
to 1.76 points) at five years postoperatively. The mean EQ-5D
score was 0.4 point preoperatively and 0.6 point at five years
postoperatively in both groups. The mean SF-12 physical com-
ponent score increased from 31 points preoperatively to ap-
proximately 39.5 points at five years postoperatively in both
groups. The mean SF-12 mental component score was ap-
proximately 50 points for both groups preoperatively and at
five years postoperatively. An analysis of outcomes according
to the femoral component shape (whether or not the trochlear
groove was appropriate for an anatomical or a domed patella)
revealed no statistically significant differences. The mean score
on question 12 of the OKS, which inquires about the ability to
walk down stairs, was 2.21 ± 1.16 points for the patellar re-
surfacing group compared with 2.33 ± 1.16 points in the non-
resurfacing group (difference, –0.09 point; 95%CI, –0.22 to 0.04
point; p = 0.152).
The percentage of patients who required readmission
and/or further interventionwas 12.1% in the patellar resurfacing
group compared with 13.1% in the nonresurfacing group (odds
ratio, 0.91; 95% CI, 0.67 to 1.23; p = 0.54) (Table II); 4.4% of
the patellar resurfacing group and 5.8% of the nonresurfacing
group required further minor or intermediate surgical proce-
dures (odds ratio, 0.74; 95% CI, 0.44 to 1.25; p = 0.27); 1.6% of
the patellar resurfacing group and 2.9% of the nonresurfacing
group required further major surgical procedures (odds ratio,
0.56; 95% CI, 0.29 to 1.06; p = 0.076); and 1.0% of the patellar
resurfacing group and 1.9% of the nonresurfacing group had
further patella-related surgery (odds ratio, 0.55; 95% CI, 0.21
to 1.34; p = 0.22). The reasons for further knee surgery included
infection, knee pain, knee stiffness, implant loosening, and knee
instability. The proportion of patients requiring further surgery
did not differ significantly between the patellar resurfacing and
Fig. 2
Comparison of the mean Oxford Knee Score (OKS) in the group allocated to receive patella resurfacing and in the group allocated to receive no patellar
resurfacing. The bars represent one standard deviation.
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nonresurfacing groups for any of the individual levels of sec-
ondary procedures.
During the first five postoperative years, 0.8% of the pa-
tellar resurfacing group and 1.9% of the nonresurfacing group
had late patellar resurfacing (odds ratio, 0.43; 95% CI, 0.16 to
1.16; p = 0.092). Patients in the patellar resurfacing group could
undergo a late resurfacing if they did not receive the allocated
resurfacing during the original operation. This was the case for
138 (16.0%) of the 861 patients allocated to receive resurfacing,
and seven (5.1%) of these patients underwent a subsequent late
resurfacing of the patella. Conversely, 759 of the 854 patients
allocated to not receive resurfacing did not undergo a resurfacing
during the primary operation, and sixteen (2.1%) of these
patients underwent late patellar resurfacing. Two patients (both
in the group allocated to resurfacing) who received a resurfacing
subsequently underwent further surgery because of a patellar
fracture.
In patients who received late patellar resurfacing, themean
OKS value deteriorated prior to the late resurfacing (Fig. 3).
The mean OKS value (and standard deviation) was 15.3 ± 8.7
points the last time it was measured before the resurfacing and
improved to 22.9± 9.6 points two years following the resurfacing,
which was still considerably lower than the mean OKS value for
the entire trial group.
Component costs were significantly higher in the patellar
resurfacing group than in the nonresurfacing group (£1603
TABLE I Patient-Assessed Outcomes at All Time Points Up to Five Years*
Allocated to Patellar
Resurfacing†
Allocated to No Patellar
Resurfacing† Difference (95% CI)‡
OKS
Baseline 18.49 ± 7.39 18.15 ± 7.66
3 months 31.19 ± 9.56 30.49 ± 9.45
1 year 34.66 ± 9.44 34.53 ± 10.16
2 years 35.61 ± 9.83 35.25 ± 10.15
3 years 35.52 ± 10.08 34.72 ± 10.41
4 years 34.93 ± 10.67 34.23 ± 10.59
5 years 35.01 ± 10.55 34.57 ± 10.25 0.59 (–0.58 to 1.76)
EQ-5D
Baseline 0.40 ± 0.30 0.39 ± 0.31
3 months 0.70 ± 0.24 0.69 ± 0.25
1 year 0.73 ± 0.25 0.71 ± 0.28
2 years 0.72 ± 0.27 0.68 ± 0.31
3 years 0.69 ± 0.30 0.65 ± 0.33
4 years 0.65 ± 0.33 0.62 ± 0.32
5 years 0.63 ± 0.34 0.61 ± 0.34 0.01 (–0.02 to 0.4)
SF-12 (v2) physical component
Baseline 31.07 ± 8.05 31.26 ± 8.5
3 months 39.42 ± 9.35 38.68 ± 9.06
1 year 40.82 ± 10.51 40.72 ± 10.39
2 years 40.66 ± 10.99 40.84 ± 10.39
3 years 40.76 ± 11.09 39.86 ± 10.92
4 years 39.74 ± 11.41 39.23 ± 10.88
5 years 39.61 ± 11.01 39.39 ± 11.48 0.23 (–0.99 to 1.46)
SF-12 (v2) mental component
Baseline 50.70 ± 11.37 49.73 ± 11.20
3 months 51.21 ± 10.60 51.14 ± 10.97
1 year 52.31 ± 10.20 51.47 ± 11.10
2 years 51.64 ± 9.95 50.87 ± 11.07
3 years 50.99 ± 9.87 50.34 ± 11.26
4 years 51.19 ± 10.22 50.10 ± 11.17
5 years 50.83 ± 10.36 50.08 ± 10.52 0.52 (–0.58 to 1.63)
*CI = confidence interval, OKS = Oxford Knee Score, EQ-5D = EuroQoL 5D, and SF-12 = Short Form-12. †Values are given as the mean and the
standard deviation. ‡Estimated with use of analysis of covariance, adjusting for minimization factors, baseline score, and surgeon. A positive
score favors patellar resurfacing.
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compared with £1519 per patient; difference, £85; 95% CI, £56
to £113; p < 0.001; see Appendix). Readmissions and subsequent
surgery accounted for 7.2% of the total cost in the patellar
resurfacing group and 11.6% in the nonresurfacing group. The
mean cost of readmission for major surgery (one-stage revision,
two-stage revision, or above-the-knee amputation) was signifi-
cantly lower in the resurfaced group (£218 per patient compared
with £491; difference, –£274; 95% CI, –£525 to –£22; p =
0.033), although there was no significant difference in themean
cost of readmission involving minor surgery (p = 0.070) or
patella-related surgery (p = 0.193). The mean cost of late pa-
tellar resurfacing, including the cost of the hospital stay, for
the twenty-three patients who received this procedure was
£3833 ± £1183.
The mean total health care cost did not differ significantly
between the patellar resurfacing and nonresurfacing groups (£7577
compared with £7726 per patient; difference, –£149; 95% CI,
–£574 to £277; p = 0.494) (see Appendix).






ing (N = 854)
Odds Ratio
95% Confidence
Interval P ValueNo. % No. %
Total no. of procedures
requiring readmission
167 202
No. of patients requiring at least
one readmission
104 12.1 112 13.1 0.91 0.67 to 1.23 0.54
Minor or intermediate operations
Total no. of operations 57 83
No. of participants requiring
At least one minor or
intermediate operation
38 4.4 50 5.8 0.74 0.44 to 1.25 0.27
Multiple minor or intermediate
operations
12 1.4 16 1.9 0.74 0.32 to 1.68 0.42
No. of participants requiring at
least one of
Wound closure 3 0.3 5 0.6 0.59 0.09 to 3.6 0.071
Debridement or exploration/washout 15 1.7 24 2.8 0.62 0.31 to 1.23 0.17
Manipulation under anesthesia 18 2.1 23 2.7 0.77 0.41 to 1.43 0.40
Arthrolysis and quadricepsplasty 1 0.1 0 0.0
Arthroscopy or examination under
anesthesia/biopsy
5 0.6 8 0.9 0.62 0.20 to 1.95 0.42
Exchange of cement spacer 0 0.0 1 0.1
Polyethylene exchange 3 0.3 5 0.6 0.59 0.09 to 3.6 0.72
Bone removal 2 0.2 0 0.0
Patella-related operations
Total no. of operations 9 1.0 16 1.9
No. of participants requiring
At least one patella-related
operation
9 1.0 16 1.9 0.55 0.21 to 1.34 0.22
Multiple patella-related operations 0 0 0 0
No. of participants requiring at
least one of
Patellar fracture treatment 2 0.2 0 0.0
Late resurfacing 7 0.8 16 1.9 0.43 0.16 to 1.16 0.09
Major operations
Total no. of operations 15 29
No. of participants requiring
At least one major operation 14 1.6 25 2.9 0.56 0.29 to 1.06 0.076
Multiple major operations 1 0.1 4 0.5
No. of participants requiring at
least one of
One-stage revision 9 1.0 11 1.3 0.83 0.37 to 1.89 0.657
Two-stage revision 6 0.7 14 1.6 0.42 0.13 to 1.17 0.11
Above-the-knee amputation 0 0.0 2 0.2
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Discussion
The results of the current study indicate that patient func-tional status, patient quality of life, and total cost during
the first five years after total knee arthroplasty are not signifi-
cantly affected by the addition of patellar resurfacing to the initial
surgical procedure. The 95% confidence interval for the differ-
ence in the OKS between the patellar resurfacing group and the
nonresurfacing group was –0.6 to 1.8 at five years postopera-
tively. A clinically important difference on the OKS scale is
believed to be approximately 3 points, and a 2-point difference
is of possible clinical significance. This study was adequately
powered to detect a clinically important difference, even taking
into account the fact that some participants did not receive the
allocated procedure. Similarly, there was no evidence of a clin-
ically relevant difference in the EQ-5D or the SF-12.
Although the proportion of patients who underwent a
patella-related reoperation was higher in the nonresurfacing
group than in the patellar resurfacing group (2% compared
with 1%), the difference was not statistically significant. The
2% rate of late resurfacing in the nonresurfacing group com-
pares favorably with those in other published series of total
knee arthroplasty in which the patella was not resurfaced12. The
rate of late resurfacing was 5% in the subgroup of patients who
were allocated to receive resurfacing during the initial operation
but did not receive resurfacing at that time. The explanation for
this observation is not obvious, but these patients may have been
more likely to request resurfacing if they were aware that they
had not received the expected patellar resurfacing previously,
or their surgeons may have been more likely to advise them to
have patellar resurfacing to treat any residual anterior knee pain.
The results of this study suggest that a patient who receives a late
resurfacing typically undergoes a gradual reduction in the knee
functional score during the years prior to the resurfacing fol-
lowed by an improvement after the resurfacing, but that the
postoperative score does not reach the typical score reached by
a patient following a first procedure. Patients to whom late re-
surfacing is recommended should be advised that this procedure
is unlikely to provide complete relief of knee pain.
Although the proportion of patients undergoing a re-
operation was higher in the nonresurfacing group than in the
resurfacing group (5.8% compared with 4.4% for minor to in-
termediate reoperation and 2.9% compared with 1.6% formajor
reoperation), the differences were not statistically significant. It is
striking that the rate of further surgery for almost every reason,
and particularly for the treatment of an infection, was higher in
the nonresurfacing group than in the resurfacing group. Never-
theless, we believe that these findings are probably due to random
variations and do not indicate clinically important differences.
Patellar resurfacing significantly increased component
costs for the primary operation by £85 (US$170 in 2007-2008)
Fig. 3
ThemeanOxford KneeScore (OKS) before and after resurfacing in the subgroup of patientswho received late patellar resurfacing, compared with themean
postoperative score of all trial participants. The bars represent one standard deviation.
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and also increased the costs associated with operating room time
and the length of the hospital stay, although the latter increases
did not reach statistical significance. A more detailed cost break-
down that specifically accounted for the cost of the bone cement
and sterilization of the instruments required for patellar resurfacing
(rather than including the latter in the operating room overhead)
might have resulted in a further slight increase in the incremental
cost of resurfacing. However, the added cost incurred during the
primary hospital stay was offset by a significant (p = 0.033)
reduction in the cost associated with readmission for major
surgery during the first five postoperative years. As a result, the
economic analysis showed that the total health care cost during
the first five years did not differ significantly between the groups.
The price that National Health Service (NHS) hospitals in the
U.K. pay for knee components is currently highly variable,
and consequently the cost at a particular hospital may differ
from the mean cost used in this analysis. However, varying the
estimated discount between 0% and 50% of the manufacturer’s
list price did not alter our overall conclusions. A full economic
evaluation is planned once all patients have been followed for
eight years.
In conclusion, on the basis of five years of follow-up, there
is no clear benefit to resurfacing the patella during total knee
arthroplasty, as resurfacing had no significant effect on patient
functional status, total treatment cost, or patient quality of life.
Five years after the total knee arthroplasty, 2% of nonresurfaced
patellae had required late resurfacing and 0.2% of resurfaced
patellae had failed because of fracture. While the number of
patellar failures may increase somewhat by ten years postopera-
tively, some surgeonsmay consider resurfacing the patella to be the
preferred option because it is expected to offer a lower reoperation
rate. Conversely, there should be no criticism of surgeonswho elect
not to resurface the patella during total knee arthroplasty, as the
majority of patients will require no further patellar surgery.
Appendix
Tables showing patient-assessed outcomes and details of
the economic analysis are available with the online ver-
sion of this article as a data supplement at jbjs.org. n
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